Pendulum Therapeutics, formerly Whole Biome, is a biotech company improving health through products targeting the microbiome.
Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases.
Pendulum was founded in 2012 by Colleen Cutcliffe, John Eid and Jim Bullard. The company is headquartered in San Francisco, California.
Pendulum introduced its first product, a medical probiotic called Pendulum Glucose Control, in January 2020. It is the only probiotic clinically shown to lower blood sugar spikes and A1C levels in people with type 2 diabetes, even on top of metformin.
Pendulum's unique, patented formula includes targeted strains discovered through DNA sequencing to meet the specific dietary needs of people with T2D. PGC is designed to address deficiencies and increase the gut microbiome's butyrate-producing and mucin-regulating functions.
Pendulum is backed by Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures, Mayo Clinic and others. The company raised $54M in Series C round on Apr 07, 2021. This brings Pendulum's total funding to $111M to date.